Oncology Unlocking the scalability of allogeneic CAR-T Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.
Oncology Bridging the innovation gap: Scalable cell therapies, adapti... Biotech must build manufacturing and trial models that make cell therapies scalable, accessible & commercially viable.
Market Access Why 70% of pharma partnership spend misses patients Finding a start-up or building an app is the cheap part; combining capabilities into something that scales across markets is the expensive part.
Digital Why AI sovereignty is becoming a requirement for businesses The companies that will lead in this next phase are those that treat AI as an integrated part of their operational architecture.
Digital AI, trust, and transformation: What the NHS needs for safe a... As AI becomes more embedded within national health system priorities, the need for clear and responsible guardrails has become increasingly critical.
R&D From in silico to in vivo: Why development strategy now dete... As discovery becomes faster and more accessible, the differentiator shifts downstream.
News argenx's Forte acquisition delivers coeliac trial win argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
